Genetic Modifiers of Parkinson's Disease: A Case–Control Study
Annals of Clinical and Translational Neurology · 2025-12 · 12 (12) · 2482-2494
DOI: 10.1002/acn3.70176 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 10.09.2025. Verfasst von Matthew J Kmiecik und 15 weiteren Autor:innen. Beteiligte Einrichtung: 23andMe, Inc., Sunnyvale, California, USA. Hauptthemen laut MEDLINE: Parkinson Disease, Glucosylceramidase, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Michael J. Fox Foundation for Parkinson's Research.
Abstract (Originalsprache)
Objective
To examine the associations of LRRK2 p.G2019S, GBA1 p.N409S, polygenic risk scores (PRS), and APOE E4 on PD penetrance, risk, and symptoms.
Methods
We conducted a US‐based observational case–control study using data from the 23andMe Inc. and Fox Insight Genetic Substudy (FIGS) databases. The total cohort included 7,586,842 participants ( n = 35,163 PD); 8791 LRRK2 p.G2019S carriers (565 with PD), 37,427 GBA1 p.N409S carriers (524 with PD), 244 dual LRRK2 /GBA1 carriers (37 with PD), and 7.5 million noncarriers (34,037 with PD). PRS was calculated from the most recently published European genome‐wide association study. Survival models estimated the cumulative incidence of PD. Logistic regressions estimated the relative odds of reporting motor and non‐motor symptoms according to genetic exposure.
Results
By the age of 80 years, the cumulative incidence of PD was 30% for dual carriers, 24% for LRRK2 p.G2019S carriers, 4% for GBA1 p.N409S carriers, and 2% for noncarriers. Higher PRS was associated with increased penetrance of the variants and earlier time to PD diagnosis. GBA1 p.N409S PD was associated with the highest burden of non‐motor symptoms, including REM sleep behavior disorder and cognitive/memory deficits, and LRRK2 p.G2019S with the lowest. APOE E4 dosage was associated with greater odds of reporting hallucinations and cognitive impairment in addition to carrier status.
Interpretation
Our findings support the use of genetic screening to enrich candidate selection for neuroprotective trials and better define outcome measures based on genetics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 23andMe, Inc., Sunnyvale, California, USA.
- The Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders, NYU Grossman School of Medicine, New York, New York, USA.
- University of Rochester Medical Center, Rochester, New York, USA.
- The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.
ORCID-Profile: Matthew J Kmiecik, Giulietta M Riboldi
Förderung
- Michael J. Fox Foundation for Parkinson's Research
Zitieren
APA
Kmiecik, M. J., Holmes, M. V., Fontanillas, P., Riboldi, G. M., Schneider, R. B., Shi, J., Guan, A., Tat, S., Micheletti, S., Stagaman, K., Gottesman, J., Hinds, D. A., Tung, J. Y., 23andMe Research Team, Aslibekyan, S., & Norcliffe-Kaufmann, L. (2025). Genetic Modifiers of Parkinson's Disease: A Case–Control Study. Annals of Clinical and Translational Neurology, 12(12), 2482-2494. https://doi.org/10.1002/acn3.70176
Vancouver
Kmiecik MJ, Holmes MV, Fontanillas P, Riboldi GM, Schneider RB, Shi J, et al. Genetic Modifiers of Parkinson's Disease: A Case–Control Study. Annals of Clinical and Translational Neurology. 2025;12(12):2482-2494. doi:10.1002/acn3.70176
BibTeX
@article{Kmiecik2025,
author = {Kmiecik, Matthew J and Holmes, Michael V and Fontanillas, Pierre and Riboldi, Giulietta M and Schneider, Ruth B and Shi, Jingchunzi and Guan, Anna and Tat, Susana and Micheletti, Steven and Stagaman, Keaton and Gottesman, Josh and Hinds, David A and Tung, Joyce Y and 23andMe Research Team, 23andMe Research Team and Aslibekyan, Stella and Norcliffe-Kaufmann, Lucy},
title = {Genetic Modifiers of Parkinson's Disease: A Case–Control Study},
journal = {Annals of Clinical and Translational Neurology},
year = {2025},
volume = {12},
number = {12},
pages = {2482--2494},
doi = {10.1002/acn3.70176}
}
EUVIMED